A common emotion recovery network across four major psychiatric disorders
Poster No:
468
Submission Type:
Abstract Submission
Authors:
Yueling Liu1, Wenqiang Xu1, Gong-Jun Ji1, Chunyan Zhu1
Institutions:
1Anhui Medical University, Hefei, Anhui Province, China
First Author:
Co-Author(s):
Introduction:
Comorbidity between psychiatric disorders is highly prevalent, which poses a serious challenge to clinical diagnosis and treatment. Abnormal emotion processing is a common characteristic across these disorders. Despite pharmacotherapy being a first-line treatment, there is a lack of consensus regarding its regulatory mechanisms in emotion processing. In this context, we aim to elucidate the mechanism of emotion recovery (ER) induced by pharmacotherapy across psychiatric disorders.
Methods:
We systematically reviewed the longitudinal studies of treatment for psychiatric disorders to identify the brain activation alterations following pharmacotherapy related to emotion processing and symptom improvement. Using novel activation network mapping approaches and a large normative connectome of 652 healthy human (validated in a data of 1000 patients with psychiatric disorder) to map the underlying brain circuits functionally associated with each experimental activation and converge them into a common network. Multiple databases are used for network validation and generalization.
On the one hand, we collected independent data of coordinates with functional or structure changes induced by pharmacotherapy to validate emotion recovery network (ERN) across imaging modalities, and extended this effect to electroconvulsive therapy (ECT). On the other hand, considering the role of ERN across various therapeutic, we also examined the relationship between brain activation associated with psychotherapy and placebo effects and the ERN network.
To further validate the ERN in the clinical application, we tested whether brain stimulation sites that were effective for improving mood disorder, such as transcranial magnetic stimulation (TMS) target atlas (Siddiqi et al., 2020), common deep brain stimulation (DBS) targets (Burke et al., 2022), and high-definition direct current stimulation (HD-tDCS) fell within the same circuit as ERN. Statistical significance was tested by permutation tests.
On the one hand, we collected independent data of coordinates with functional or structure changes induced by pharmacotherapy to validate emotion recovery network (ERN) across imaging modalities, and extended this effect to electroconvulsive therapy (ECT). On the other hand, considering the role of ERN across various therapeutic, we also examined the relationship between brain activation associated with psychotherapy and placebo effects and the ERN network.
To further validate the ERN in the clinical application, we tested whether brain stimulation sites that were effective for improving mood disorder, such as transcranial magnetic stimulation (TMS) target atlas (Siddiqi et al., 2020), common deep brain stimulation (DBS) targets (Burke et al., 2022), and high-definition direct current stimulation (HD-tDCS) fell within the same circuit as ERN. Statistical significance was tested by permutation tests.
Results:
Twenty-three experiments from 20 studies were enrolled, involving 382 psychiatric patients and 241 health participants. Although the pharmacotherapy-induced activation changes during emotion processing were widely distributed in the brain, these regions were functionally connected. We found that 91% of heterogeneous brain activation were successfully mapped into a common network centered at the bilateral insular and putamen (Figure 1). This common network was validated by independent datasets across imaging modalities, and could be generalized to brain stimulation therapies (Figure 2). Cross-modality and cross-therapy validation indicated that the ERN showing stronger functional connectivity in brain regions with structural and functional changes after medication and ECT treatment, but this connection was not replicated in brain activation changes after psychotherapy and placebo therapy (Figure 2A). TMS, DBS and HD-tDCS targets that related to emotion-recovery have stronger functional connectivity with the ERN than random networks (r = 0.86, P < 0.0005; t= -3.51, P < 0.0001; t= -2.48, P < 0.0001; Figure 2B-D). More interestingly, we observed that HD-tDCS targets had different polarity responses to the ERN positive and negative correlation network (anodic targets had stronger positive connections with ERN, and cathodic targets had stronger negative connections with ERN).
·Figure 1. Activation network mapping (ANM) of emotion recovery in psychiatric disorders induced by pharmacotherapy.
·Figure 2. Validation and clinical implication of ERN. (A) Cross-modality and cross-therapy validation.
Conclusions:
The emotion-processing-related regions modulated by pharmacotherapy in psychiatric disorders converge on a common brain network. This research contributes to understanding the mechanism of normalizing emotion processing in psychiatric disorders and provides a potential basis for developing transdiagnostic treatment strategies.
Disorders of the Nervous System:
Psychiatric (eg. Depression, Anxiety, Schizophrenia) 1
Emotion, Motivation and Social Neuroscience:
Emotional Perception 2
Modeling and Analysis Methods:
Activation (eg. BOLD task-fMRI)
Connectivity (eg. functional, effective, structural)
Novel Imaging Acquisition Methods:
Multi-Modal Imaging
Keywords:
Affective Disorders
Emotions
Psychiatric Disorders
Other - Emotion-processing recovery/activation network mapping/Pharmacotherapy
1|2Indicates the priority used for review
Abstract Information
By submitting your proposal, you grant permission for the Organization for Human Brain Mapping (OHBM) to distribute your work in any format, including video, audio print and electronic text through OHBM OnDemand, social media channels, the OHBM website, or other electronic publications and media.
The Open Science Special Interest Group (OSSIG) is introducing a reproducibility challenge for OHBM 2025. This new initiative aims to enhance the reproducibility of scientific results and foster collaborations between labs. Teams will consist of a “source” party and a “reproducing” party, and will be evaluated on the success of their replication, the openness of the source work, and additional deliverables. Click here for more information. Propose your OHBM abstract(s) as source work for future OHBM meetings by selecting one of the following options:
Please indicate below if your study was a "resting state" or "task-activation” study.
Healthy subjects only or patients (note that patient studies may also involve healthy subjects):
Was this research conducted in the United States?
Were any human subjects research approved by the relevant Institutional Review Board or ethics panel? NOTE: Any human subjects studies without IRB approval will be automatically rejected.
Were any animal research approved by the relevant IACUC or other animal research panel? NOTE: Any animal studies without IACUC approval will be automatically rejected.
Please indicate which methods were used in your research:
For human MRI, what field strength scanner do you use?
Which processing packages did you use for your study?
Provide references using APA citation style.
Siddiqi, S. H., Taylor, S. F., Cooke, D., Pascual-Leone, A., George, M. S., & Fox, M. D. (2020). Distinct Symptom-Specific Treatment Targets for Circuit-Based Neuromodulation. Am J Psychiatry, 177(5), 435-446.